AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

A promising new drug may finally bring hope to people suffering from a common but often overlooked cause of high blood ...

PFAS, or forever chemicals, can wreak havoc on the body, disrupting hormones and impacting the immune system. Now, ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the second quarter of 2025 and upped annual ...

Researchers at the German Centre for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of heart failure that has so far been difficult to treat. Prof. Johannes Backs, ...

Game Changers in Nephrology' was the theme of the 62nd European Renal Association (ERA) Congress, held in Vienna, ...

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sl ...